Skip to content

CervoMed Inc.: 10-K filed 2023-03-24

What CervoMed Inc. reported in its annual report filed 2023-03-24 (fiscal FY 2022): 30 published measures, 62 facts as tagged in accession 0001437749-23-007795.

This filing

Form
10-K (annual report)
Filed
2023-03-24
Fiscal period
fiscal FY 2022
Accession
0001437749-23-007795 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CervoMed Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-12-3122,635,052USD
At 2021-12-3137,839,151USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-12-312,417,336USD
At 2021-12-312,927,684USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-12-3120,217,716USD
At 2021-12-3134,911,467USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-12-3110,113,706USD
At 2021-12-3137,313,558USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,591,428USD365
2021-01-01 to 2021-12-31-24,095,727USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-14,969,114USD365
2021-01-01 to 2021-12-31-14,501,789USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-12-315,000USD365
2021-01-01 to 2021-12-3133,295,752USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-12,235,738USD365
2021-01-01 to 2021-12-314,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-12-31-145,596,539USD
At 2021-12-31-130,005,111USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-7.65USD/shares365
2021-01-01 to 2021-12-31-12.38USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2022-01-01 to 2022-12-312,038,891USD/shares365
2021-01-01 to 2021-12-311,946,859USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-31-443,893USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-12-31928,052USD365
2021-01-01 to 2021-12-31897,260USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,972,180USD365
2021-01-01 to 2021-12-31-24,677,107USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-12-3122,635,052USD
At 2021-12-3137,823,573USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-12-311,127,782USD
At 2021-12-31947,495USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-01-01 to 2022-12-317,237,165USD365
2021-01-01 to 2021-12-318,499,414USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-12-312,039,557shares
At 2021-12-312,038,185shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2022-12-3110,113,706USD
At 2021-12-3137,313,558USD
At 2020-12-3118,515,595USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-12-31165,847,590USD
At 2021-12-31164,914,540USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2022-12-31-35,375USD
At 2021-12-310USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2022-12-3120,217,716USD
At 2021-12-3134,911,467USD
At 2020-12-3124,814,182USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2022-12-310USD
At 2021-12-3115,578USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2022-12-310USD
At 2021-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,591,428USD365
2021-01-01 to 2021-12-31-24,539,620USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,626,803USD365
2021-01-01 to 2021-12-31-24,095,727USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-318,735,015USD365
2021-01-01 to 2021-12-317,445,277USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-3193,416USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-31-443,893USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-3131,094,302USD365

Inspect the source

Entity
CervoMed Inc. / CIK 0001053691
Captured
2026-09-20T05:17:36.273Z
SEC response SHA-256
0a28d9e08b18175e4a16bd2486e9ebae9dc8a6e8a3f7e429c0f71f98175b0255

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053691.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))